Trial Profile
Phase 1 Trial of Bevacizumab Treatment for Severe Retinopathy of Prematurity
Status:
Completed
Phase of Trial:
Phase I
Latest Information Update: 07 Nov 2022
Price :
$35
*
At a glance
- Drugs Bevacizumab (Primary)
- Indications Retinopathy of prematurity
- Focus Therapeutic Use
- Acronyms ROP1
- 05 Nov 2021 Status changed from active, no longer recruiting to completed.
- 01 Jul 2019 Status changed from recruiting to active, no longer recruiting.
- 19 Jun 2018 Status changed from suspended to recruiting.